Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Pfizer Says Endpoints Not Met in 2nd Bapineuzumab Study

Paul Quintaro, Benzinga Staff Writer
August 06, 2012 4:03 PM
+ Follow
Print
Email
Tickers: PFE
Benzinga Share:

Pfizer Inc. (NYSE: PFE) announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 301). Pfizer and Janssen AI are partners in the Alzheimer's Immunotherapy Program (AIP).

(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted in: News, Financing

 

Around the Web, We're Loving...

Rev. Michael Reilly: NY Marathon Only Making Matters Worse in City
Oil, Gasoline Pounded; East Coast Supplies Eyed
A Microsoft Smartphone? After Surface Tablet, It Might Just Happen
Jobs Rose 171,000 In October; Unemployment Rate 7.9%
McDonald's No Longer Overcooked

Most Popular

Study: Amazon is Nibbling Netflix's Lunch
UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Starbucks Corporation
The Week Ahead: More Earnings and the U.S. Election
Stocks Fall to End Week, Dow Down Triple Digits
Is Jack in the Box the Next Big Restaurant Stock?
GNC Could Make Your Portfolio Big & Strong

Related Articles (PFE)

US Stock Futures Down Ahead Of Economic Data
Earnings Scheduled For November 1, 2012
Stocks To Watch For November 1, 2012
More Equal-Weight ETFs Your Broker Forgot to Mention
Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)
S&P Likes a Trio of Biotech ETFs

Partner Network

Posts by Paul Quintaro

Benzinga Professional

Subscribe

Benzinga's News Delivered Free

Brain Trust

See All Brain Trust Columnists